T1D Prevention and Cure
T1D Prevention and Cure: Where Research Is Now
A friend asks at the school gate whether the cure is close. A clinic letter mentions teplizumab and you have not heard the word before. A news clip shows someone walking out of a hospital making their own insulin again, and the story does not say what happened the year after. The science behind these moments is moving faster than it has in thirty years; what families and teams need is a map of where the work actually is, not a headline of where it might be.
Ask Grace
Want to ask which trial sits behind a specific cure-research claim, or where a particular therapy is in the pipeline today? Ask Grace.
Four parallel programmes of work
Most coverage of a T1D cure flattens the field into a single race against a single clock. The reality is four parallel programmes of work, each with its own evidence base, its own time horizon, and its own honest gap. The guide that follows holds those four lanes apart on purpose, so that a family question (“is teplizumab right for us?”) and a research question (“when does VX-880 read out the phase 3?”) can each find their own page without bleeding into the other. None of these four lanes, on its own, is a cure. Together they are how a cure (or, more likely, a layered set of cures for different parts of the disease) actually arrives.
How to use this guide
The four parts are designed to stand alone. Read in order if it helps the picture come together; jump straight to the part that matches the conversation in front of your family or your team if it does not. Each part anchors on the trial evidence, frames where it sits in clinic practice today, and closes with what families and teams can actually do with the information.
Part 1: Staging and Screening, Finding T1D Before the Diagnosis
The Insel 2015 framework (Stage 1, Stage 2, Stage 3) is now the international way of speaking about pre-symptomatic T1D. Population screening programmes (Fr1da in Bavaria, ELSA in the UK, EDENT1FI across Europe, T1DETECT in the US) identify children years before clinical onset. Continuous glucose monitoring is starting to replace the oral glucose tolerance test for surveillance. The decision to screen, and what to do with the answer, sits with the family.
Part 2: Disease-Modifying Therapy, the Immunotherapy Pipeline
The first medicine licensed to delay clinical T1D, teplizumab, modulates the immune attack on the insulin-producing cells. The wider pipeline includes anti-thymocyte globulin, abatacept, golimumab, verapamil (off-patent, repurposed), and combination approaches. The honest framing is that benefit consistently fades when treatment stops; the field’s current direction is toward combinations and personalised strategies rather than single agents.
Part 3: Beta-Cell Replacement and Regeneration
Stem-cell-derived islets (Vertex VX-880, now zimislecel) achieved insulin independence in early-phase trials at the cost of chronic immunosuppression. Encapsulation approaches aim to remove the immunosuppression requirement; cadaveric islet transplantation remains the regulatory baseline for adults with severe hypo-unawareness. These are early-phase approaches; the language used to describe them in the news is often ahead of where the evidence actually sits.
Part 4: Next-Generation Insulins
While the cure work continues, the insulin itself keeps improving. Once-weekly basal insulin (icodec) reached non-inferiority against daily basal in T1D in ONWARDS 6. Faster-acting prandials (Fiasp, Lyumjev) are licensed and in routine use. Glucose-responsive (smart) insulins are in early-phase development. The point of this part is that better insulin is still a cure-research story: most people with T1D today will be using next-generation insulins long before any of the other three domains arrives at scale.
What carries across the four domains
The thread that joins the four lanes is something families and clinicians already sense in the gap between a news headline and a clinic conversation. The body talks back honestly through the glucose, in every age band; what shifts in the cure-research story is the kind of help science can offer. Stage 2 has gone from a research category to a clinic decision. Beta-cell replacement has moved from a paper proposition to a small but real cohort of trial participants who have, for a time, made their own insulin again. Next-generation insulins have made the day-to-day arithmetic gentler without anyone calling it a cure. Population screening has moved from the academic literature to letters that arrive on kitchen tables in eight European countries.
What does not change across any of this is that science moves at the speed of evidence and rollout moves at the speed of health systems. Headlines compress both into a single dramatic moment; clinic practice does not work like that. Population averages get most of the way there, the final twenty percent takes the family, the team, and the conversation. The trial result is the start of the conversation, not the end of it.
Each domain is a parallel programme of work; none, on its own, is a cure. The route to a clinical cure (or, more likely, a layered set of cures for different parts of the disease) runs through more than one of these four lanes at once.
Acknowledgements
This guide draws on the international cure-research evidence base curated for GNL Grace; the per-part references for each domain live on the four part pages, with full trial detail one click away in the disclosures. Thanks to the families at Birmingham Women’s and Children’s NHS Foundation Trust whose questions shape every page on this site, and to the wider international research community whose work this guide tries to translate honestly.